Abstract:6012 Background: Prognosis of nasopharyngeal carcinoma (NPC) with stage T any N3M0 remains unsatisfactory due to high-risk of distant metastasis, indicating the need of more comprehensive treatment strategy. Synergistic effects are observed when immune checkpoint blockade anti-PD-1 is combined with chemotherapy or anti-angiogenic agents. This trial investigated the efficacy and safety of anti-PD-1 camrelizumab and anti-angiogenic agent apatinib in combination with induction chemotherapy and concurrent chemoradiotherapy (CCRT) in patients with T any N3M0 NPC. Methods: In this phase II trial, patients with T any N3M0 NPC (AJCC 8 th edition) were enrolled and treated with induction chemotherapy (NAB-paclitaxel, 200 mg/m 2 , day 1; cisplatin 60 mg/m 2 , day 1; and capecitabine, 1000 mg/m 2 , orally twice a day, days 1-14; every 21-day for 3 cycles) and apatinib (250 mg, 5 days/week, for up to 8 weeks), followed by CCRT (cisplatin, 100 mg/m 2 , day 1, every 21-day for 2 cycles and IMRT). Camrelizumab (200 mg once every 3 weeks) was given from the first cycle of induction chemotherapy until one year. Prescribed radiation doses were 68-72 Gy, 64-68 Gy, 60-64 Gy, and 54-58 Gy in 30-33 fractions for PTVnx, PTVnd, PTV high-risk , and PTV low-risk , respectively. Primary endpoint was 1-year distant metastasis-free survival (DMFS). Patient’s response to the therapy was evaluated using RECIST 1.1. Results: From May 2020 to July 2021, 50 eligible patients were enrolled. Median age was 45 years (range 20-65), median EBV DNA concentration was 4520 copy/ml (IQR 1595-17550), and 13 patients (26%) were female. Among 50 patients evaluable for response assessment after induction therapy, all patients had overall response, including 12 patients (24%) with complete response (CR). After 1-3 cycles of induction therapy, 84.8% (28/33 available) patients achieved negative pathological finding in the primary tumor site from endoscopic biopsy and 50% (17/34 available) from lymph nodes biopsy. Except one patient achieved regional partial response and one patient died from liver and bone metastases, the other patients all achieved CR at 3 months after radiotherapy. One-year DMFS rate was 98% (95% CI 96-100) with a median follow-up of 12.3 months (range 6.4-20.2). Grade ≥3 toxicity appeared in 32 (64%) of 50 patients and mainly consisted of nausea/vomiting (9 [18%]), neutropenia (8 [16%]), leukopenia (7 [14%]), anemia (7 [14%]), rash (5 [10%]) and thrombocytopenia (5 [10%]). Safety profile was anticipated without treatment or immune-related deaths. Conclusions: Camrelizumab and apatinib combined with induction chemotherapy of NAB-paclitaxel, cisplatin and capecitabine and CCRT shows excellent distant metastatic control with acceptable safety, which is a new promising and effective systemic therapy regimen for high-risk of metastatic NPC patients. Clinical trial information: ChiCTR2000032317.

Primary Study in Experimental Antiangiogenic Therapy of Nasopharyngeal Carcinoma with Agm-1470 (Tnp-470)

Combination of Angiogenesis Inhibitor TNP-470 with Cytotoxic Drugs in Experimental Therapy of Nasopharyngeal Carcinoma.

Anti-tumor Effect of Angiogenesis Inhibitor TNP-470 on the Human Nasopharyngeal Carcinoma Cell Line NPC/HK1.

Gene Therapy for Human Nasopharyngeal Carcinoma by Adenovirus-Mediated Transfer of Human P53, GM-CSF, and B7-1 Genes in a Mouse Xenograft Tumor Model.

Comprehensive Immune Landscape and Molecular Characteristics of Clinical Responses to Chemotherapy, Antiangiogenic Agents and PD-1 Inhibitors in Advanced Nasopharyngeal Cancer

Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts.

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.

Suppressing Tumor Growth of Nasopharyngeal Carcinoma by Htertc27 Polypeptide Delivered Through Adeno-Associated Virus Plus Adenovirus Vector Cocktail

Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts

Camrelizumab, apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma

Study on the radiotherapy effect and serum neutral granulocyte lymphocyte ratio and inflammatory factor expression of nasopharyngeal carcinoma

Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Preliminary Study of Conventional Radiotherapy Combined with Nicotinamide and Carbogen in the Treatment for Nasopharyngeal Carcinoma

Polo‐like Kinase 1 Inhibitor NMS‐P937 Represses Nasopharyngeal Carcinoma Progression Via Induction of Mitotic Abnormalities

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ill Study Of Anlotinib Or Placebo In Combination With Gemcitabine And Cisplatin (Gp) As First -Line Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma (R/M Npc).

Noninvasive Monitoring of Early Antiangiogenic Therapy Response in Human Nasopharyngeal Carcinoma Xenograft Model Using MRI with RGD-conjugated Ultrasmall Superparamagnetic Iron Oxide Nanoparticles

ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.

Efficacy and Safety of Camrelizumab and Apatinib Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy for Stage T Any N3M0 Nasopharyngeal Carcinoma: A Phase II QUINTUPLED Trial.

Saucerneol Attenuates Nasopharyngeal Carcinoma Cells Proliferation and Metastasis Through Selectively Targeting Grp94

Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies

Serum Angiogenin Concentration in Nasopharyngeal Carcinoma Patients and Its Clinical Significance